Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | RARB | P10826 | 8/20 | 0.47 |
| ▸ | THRB | P10828 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 2/20 | 0.41 |
| ▸ | MPL | P40238 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12834392 | 0.90 | TP53 (0.42) | MAPTSMN1; SMN2THRBALDH1A1KMT2A | |
| SCHEMBL12834692 | 0.84 | RARB (0.45) | MAPTRARBMEN1ALDH1A1RARA | |
| SCHEMBL13026018 | 0.81 | HRH3 (0.43) | MAPTSMN1; SMN2RARBMEN1ALDH1A1 | |
| SCHEMBL13025840 | 0.81 | RARB (0.49) | MAPTSMN1; SMN2RARBTHRBMEN1 | |
| SCHEMBL13025924 | 0.80 | RARB (0.38) | RARBRARAMPL | |
| SCHEMBL10922933 | 0.80 | RARB (0.65) | MAPTSMN1; SMN2RARBTHRBMEN1 | |
| SCHEMBL13025841 | 0.80 | THRB (0.44) | MAPTSMN1; SMN2RARBTHRBMEN1 | |
| SCHEMBL10924225 | 0.79 | RARB (0.64) | MAPTSMN1; SMN2RARBTHRBMEN1 | |
| SCHEMBL9405901 | 0.79 | RARB (0.53) | MAPTSMN1; SMN2RARBTHRBMEN1 | |
| SCHEMBL9405742 | 0.79 | RARB (0.53) | MAPTSMN1; SMN2RARBTHRBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838087-B2 | Benzene derivative, liquid crystal composition and liquid crystal display device | CHISSO CORPORATION (JP) | 2010-11-23 | — | — | US | disclosed |
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | JNC PETROCHEMICAL CORPORATION (JP) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070200092-A1 | Benzene Derivative, Liquid Crystal Composition And Liquid Crystal Display Device | CCND2, YBX1, CNKSR1 | MAPT 1989/4885SMN1; SMN2 3745/4885RARB 228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.